Investigational MenC-CRM + LHD153R

Investigational MenC-CRM + LHD153R is a combination vaccine candidate under investigation. "MenC-CRM" refers to a meningococcal group C conjugate vaccine in which the capsular polysaccharide from *Neisseria meningitidis* serogroup C is conjugated to the CRM197 protein, a non-toxic mutant of diphtheria toxin commonly used as a carrier protein in conjugate vaccines[6]. Such vaccines induce T-cell dependent immune responses and are designed to protect against invasive disease caused by *Neisseria meningitidis* group C. The addition of "LHD153R" suggests inclusion of another component or adjuvant, but there is no publicly available information on "LHD153R" as an established vaccine component or adjuvant. The combination is likely being developed for enhanced immunogenicity against meningococcal disease (serogroup C), possibly with novel adjuvantation or delivery technology.

Other names

MenC-CRMLHD153RLHD-153RLHD 153R